Characterization of immunoliposomes for HER2-targeted delivery of the dual Rac/Cdc42 inhibitor MBQ-167

被引：0
|
作者：
Velazquez, Luis E.
Dharmawardhane, Suranganie
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1998
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1998
引用
收藏
页数：2
相关论文
共 30 条
  • [1] Characterization of immunoliposomes for HER2-targeted delivery of the dual Rac/Cdc42 inhibitor MBQ-167
    Velazquez-Vega, Luis
    Dharmawardhane, Suranganie
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (03) : S116 - S117
  • [2] Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer
    Humphries-Bickley, Tessa
    Castillo-Pichardo, Linette
    Hernandez-O'Farrill, Eliud
    Borrero-Garcia, Luis D.
    Forestier-Roman, Ingrid
    Gerena, Yamil
    Blanco, Manuel
    Rivera-Robles, Michael J.
    Rodriguez-Medina, Jose R.
    Cubano, Luis A.
    Vlaar, Cornelis P.
    Dharmawardhane, Suranganie
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (05) : 805 - 818
  • [3] The dual Rac/Cdc42 inhibitor MBQ-167 and derivatives as anticancer compounds
    Castillo-PIchardo, Linette
    Maldonado, Maria Del Mar
    Ruiz-Calderon, Jean
    Rodriguez-Orengo, Jose F.
    Hernandez, Eliud
    Vlaar, Cornelis
    Flanagan, Surangani F. Dharmawardhane
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [4] Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer
    Velazquez-Vega, Luis E.
    Rivera-Robles, Michael
    Sanchez-Alvarez, Annelis O.
    Vivas-Mejia, Pablo E.
    Aponte-Reyes, Miciely
    Cruz-Collazo, Ailed M.
    Grafals-Ruiz, Nilmary
    Dorta-Estremera, Stephanie
    Hernandez-O'Farrill, Eliud
    Vlaar, Cornelis P.
    Dharmawardhane, Suranganie
    TRANSLATIONAL ONCOLOGY, 2024, 44
  • [5] Efficacy of the Rac/Cdc42 inhibitor MBQ-167 in combination therapy with Paclitaxel
    Cruz-Collazo, Ailed M.
    Katsara, Olga
    Salvo, Elizabeth
    Ruiz, Jean
    Schneider, Robert
    Dharmawardhane, Suranganie
    CANCER RESEARCH, 2022, 82 (12)
  • [6] Overcoming Therapy Resistance in HER2-positive Breast Cancer with the Dual Rac/Cdc42 Inhibitor MBQ-167
    Velazquez-Vega, Luis
    Rivera-Robles, Michael
    Vigo-Morales, Paula
    Dharmawardhane, Suranganie
    FASEB JOURNAL, 2021, 35
  • [7] Interaction site elucidation of the Rac1/Cdc42 inhibitor, MBQ-167
    Medina, Julia, I
    Bayro, Marvin
    Hernandez, Eliud
    Vlaar, Cornelis
    Gonzalez, Ricardo
    Dharmawardhane, Suranganie
    CANCER RESEARCH, 2020, 80 (16)
  • [8] Investigating potential off-target effects of the dual Rac and Cdc42 inhibitor MBQ-167
    Picon, Hector M.
    Maldonado, Maria Del Mar
    Flanagan, Surangani F. Dharmawardhane
    CANCER RESEARCH, 2020, 80 (16)
  • [9] The potential therapeutic effect of the Rac/Cdc42 inhibitor MBQ-167 in glioblastoma in vitro
    Almedina, Derealise Garcia
    Grafals-Ruiz, Nilmary
    Dharmawardhane, Suranganie
    Torres-Sanchez, Anamaris
    CANCER RESEARCH, 2023, 83 (07)
  • [10] MBQ-167, a Rac/Cdc42 targeted therapeutic, in combination with paclitaxel for TNBC treatment
    Ruiz-Calderon, Jean
    Lopez-Lopez, Irmaris
    Cruz-Collazo, Ailed
    Dharmawardhane, Suranganie
    CLINICAL CANCER RESEARCH, 2020, 26 (12) : 26 - 27
123